



ADDRESS: 26 Amber Court, 1 Bride Street, N7 8PY London, United Kingdom

BORN: January 1, 1988

NATIONALITY: Swedish

REBECKA ISAKSSON *CURRICULUM VITAE*

SUMMARY

PhD in Pharmaceutical science with good training in drug discovery and development. PhD project focused on synthetic organic chemistry of small molecules to explore the structure-activity relationship, metabolic stability, and functional activity of a hit compound. Previous postdoctoral experience in peptide synthesis and fluorescence labeling. Current postdoctoral research project focused on bioconjugation and liposome formulation of antimicrobial lantibiotics to target Gram-negative bacteria. Extracurricular activities focused on strategic governance and professional development for young pharmacists and pharmaceutical scientist.

PROFESSIONAL PREPARATION

PhD in Pharmaceutical Sciences	Faculty of Pharmacy, Uppsala University	2014-19
Title: <i>Ligands of the Angiotensin II type 2 receptor – Exploring structure and function of ligand C38</i>		
Courses and research project (medicinal chemistry)	Stockholm University/Karolinska Institute	2013
Master of Science in Engineering in Chemistry	Royal Institute of Technology (KTH)	2007-12
Title: <i>Synthetic Approach to Dehaloperophoramidine via a Samarium Mediated Reductive Dialkylation</i>		

APPOINTMENTS

Postdoctoral Researcher	UCL, Department of Chemistry	Current
Postdoctoral Researcher	School of Biology, University of Edinburgh	2019-20
Teacher in organic chemistry, 0.2 FTE	Faculty of Pharmacy, Uppsala University	2014-19
Teacher in chemistry, biology, and math	Jensen Vuxenutbildning (University prep.)	2013

ADDITIONAL EXPERIENCE

Chair of SIG New Generation of Pharmaceutical Scientist	FIP (fip.org)	2018-
Member of Faculty of pharmacy reorganization workgroup	Uppsala University	2018-19
Chair of Organizing committee of the first FIP Young Scientist Conference	FIP (fip.org)	2015-17
Member of Committee for Research education at Medical/Pharmacy domain	Uppsala University	2016-17
Chair of Pharmaceutical PhD student council	Uppsala University	2015-16
Member of Executive Committee for Scientific domain Medicine/Pharmacy	Uppsala University	2015-16
Member of Board for Scientific domain Medicine/Pharmacy	Uppsala University	2015-16
Member of Board for Department of Medicinal chemistry	Uppsala University	2014-17

FUNDING

Wellcome ISSF Researcher Restarting Grant	(£20 000)	2022
Göran Schills stiftelse – Postdoc scholarship	(SEK 410 000)	2021
Elisabet och Alfred Ahlqvist Stiftelse – Postdoc scholarship	(SEK 300 000)	2020
Stiftelsen Bengt Lundqvists Minne – Postdoc scholarship	(SEK 400 000)	2020-21
Sederholms Nordiska – research grant	(SEK 31 000)	2018
Awarded 7 travel grants for participation in international conferences	(SEK 85 000)	2014-18

COURSES and EXCHANGE PROGRAMS

13 th ULLA Summer research school, 7-15 July, Belgium	3.0 credits	2017
1 st ULLA Summer workshop, 13-15 July, Belgium	1.0 credits	2016
Drug discovery and development – Research school	15.0 credits	2015
Academic Teacher Training Course (5 weeks)	7.5 credits	2014
CHUST Exchange program	City College New York	2010, 11

PEER-REVIEWED RESEARCH PAPERS and BOOK CHAPTERS

1. D. Harbottle, P. Bueno, **R. Isaksson**, I. Kretzschmar*: Coalescence of particle-laden drops with a planar oil-water interface.
J. Colloid Interface Sci., 362 (2011), 235-241. DOI: 10.1016/j.jcis.2011.05.077
2. **M. Larhed**, **R. Isaksson**, **A. Hallberg**: Chapter 18 - Discovery of Nonpeptide, Selective AT2 Receptor Agonists. In *The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications*, Academic Press, 2015, 131-140.
Part of DOI: 10.1016/B978-0-12-801364-9.00018-3
3. **R. Isaksson**, I. Kumpiņa, M. Larhed, J. Wannberg*: Rapid and straightforward transesterification of sulfonyl carbamates.
Tetrahedron Lett., 57 (2016), 1476-1478. DOI: 10.1016/j.tetlet.2016.02.071
4. I. Kumpiņa, **R. Isaksson**, J. Sävmarker, J. Wannberg, M. Larhed*: Microwave Promoted Transcarbamylation Reaction of Sulfonylcarbamates under Continuous-Flow Conditions.
Org. Process Res. Dev., 20 (2016), 440-445. DOI: 10.1021/acs.oprd.5b00323
5. B. Page, N. Valerie, R. Wright, O. Wallner, **R. Isaksson**, M. Carter, S. Rudd, A-S. Jemth, I. Almlöf, J. Font-Matue, S. Ilona-Minguez, P. Baranczewski, F. Jeppsson, E. Homan, H. Almqvist, H. Axelsson, S. Regmi, A-L. Gustavsson, T. Lundbäck, M. Scobie, K. Strömberg, P. Stenmark, M. Beato, T. Helleday*: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.
Nat. Commun., 9 (2018), art. nr. 250. DOI: 10.1038/s41467-017-02293-7
6. J. Wannberg, **R. Isaksson**, U. Bremberg, M. Backlund, J. Sävmarker, M. Hallberg, M. Larhed*: A convenient transesterification method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes.
Bioorg. Med. Chem. Lett., 28 (2018), 519-522. DOI: 10.1016/j.bmcl.2017.11.042
7. **R. Isaksson**, J. Lindman, J. Sallander, J. Wannberg, M. Backlund, D. Baraldi, R. Widdop, M. Hallberg, J. Åqvist, H. Gutierrez de Teran, J. Gising, M. Larhed*: A Series of Analogues to the AT₂R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode.
ChemistryOpen, 8 (2019), 114-125. DOI: 10.1002/open.201800282
8. **R. Isaksson***, A. Casselbrant*, E. Elebring, M. Hallberg, M. Larhed, L. Fändriks: Direct stimulation of the angiotensin II type 2 receptor reduce nitric oxide production in lipopolysaccharide treated mouse macrophages.
Eur. J. Pharmacol., 868 (2020), 172855. DOI: 10.1016/j.ejphar.2019.172855
9. J. Z. Patel, L. Sandberg, J. Wannberg, M. Backlund, J. Gising, Y. Gravenfors, M. Hallberg, **R. Isaksson***, and M. Larhed*: From virtual screening to selective angiotensin II type 2 receptor ligands with promising in vivo pharmacokinetic profile.
Manuscript
10. S. Shave, **R. Isaksson**, N.T. Pham, R.J.R. Elliott, J.C. Dawson, J. Soudant, N.O. Carragher, and M. Auer*: Discovery and profiling of a nullomer tetrapeptide.
Manuscript

* Corresponding author